This Article Figures Only Full Text Full Text (PDF) Online Appendix View CVN News Brief All Versions of this Article: j.jacc.2009.03.005v1 53/18/1629    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Douglas, P. S. Articles by Peterson, E. D. Search for Related Content PubMed PubMed Citation Articles by Douglas, P. S. Articles by Peterson, E. D. Related Collections Related Article

LATE-BREAKING CLINICAL TRIAL

Clinical Effectiveness of Coronary Stents in Elderly Persons

Results From 262,700 Medicare Patients in the American College of Cardiology–National Cardiovascular Data Registry

Pamela S. Douglas, MD^_*,_*, J. Matthew Brennan, MD^_*, Kevin J. Anstrom, PhD^_*, Art Sedrakyan, MD, PhD, Eric L. Eisenstein, DBA^_*, Ghazala Haque, MBBS, MHS^_*, David Dai, PhD^_*, David F. Kong, MD^_*, Bradley Hammill, PhD^_*, Lesley Curtis, PhD^_*, David Matchar, MD^_*, Ralph Brindis, MD^, and Eric D. Peterson, MD, MPH^_*

^_* Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina
Agency for Healthcare Quality and Research, Rockville, Maryland
Kaiser Permanente, Oakland, California
American College of Cardiology, Washington, DC

Manuscript received February 13, 2009; revised manuscript received March 5, 2009, accepted March 9, 2009.

^_* Reprint requests and correspondence: Dr. Pamela S. Douglas, 7022 North Pavilion DUMC, P.O. Box 17969, Durham, North Carolina 27715 (Email: pamela.douglas{at}duke.edu).

Objectives: The aim of this study was to compare outcomes in older individuals receiving drug-eluting stents (DES) and bare-metal stents (BMS).

Background: Comparative effectiveness of DES relative to BMS remains unclear.

Methods: Outcomes were evaluated in 262,700 patients from 650 National Cardiovascular Data Registry sites during 2004 to 2006 with procedural registry data linked to Medicare claims for follow-up. Outcomes including death, myocardial infarction (MI), revascularization, major bleeding, stroke, death or MI, death or MI or revascularization, and death or MI or stroke were compared with estimated cumulative incidence rates with inverse probability weighted estimators and Cox proportional hazards ratios.

Results: The DES were implanted in 217,675 patients and BMS were implanted in 45,025. At 30 months, DES patients had lower unadjusted rates of death (12.9% vs. 17.9%), MI (7.3 of 100 patients vs. 10.0 of 100 patients), and revascularization (23.0 of 100 patients vs. 24.5 of 100 patients) with no difference in stroke or bleeding. After adjustment, DES patients had lower rates of death (13.5% vs. 16.5%, hazard ratio [HR]: 0.75, 95% confidence interval [CI]: 0.72 to 0.79, p < 0.001) and MI (7.5 of 100 patients vs. 8.9 of 100 patients, HR: 0.77, 95% CI: 0.72 to 0.81, p < 0.001), with minimal difference in revascularization (23.5 of 100 patients vs. 23.4 of 100 patients; HR: 0.91, 95% CI: 0.87 to 0.96), stroke (3.1 of 100 patients vs. 2.7 of 100 patients, HR: 0.97, 95% CI: 0.88 to 1.07), or bleeding (3.4 of 100 patients vs. 3.6 of 100 patients, HR: 0.91, 95% CI: 0.84 to 1.00). The DES survival benefit was observed in all subgroups analyzed and persisted throughout 30 months of follow-up.

Conclusions: In this largest ever real-world study, patients receiving DES had significantly better clinical outcomes than their BMS counterparts, without an associated increase in bleeding or stroke, throughout 30 months of follow-up and across all pre-specified subgroups.

Key Words: comparative effectiveness • coronary revascularization • drug-eluting stent

Abbreviations and Acronyms   ACC = American College of Cardiology   BMS = bare-metal stent(s)   CABG = coronary artery bypass grafting   CI = confidence interval   DES = drug-eluting stent(s)   FDA = Food and Drug Administration   HR = hazard ratio   IPW = inverse propensity weighted scoring   MI = myocardial infarction   NCDR = National Cardiovascular Data Registry   NSTEMI = non–ST-segment elevation myocardial infarction   PCI = percutaneous coronary intervention   RCT = randomized controlled trial   STEMI = ST-segment elevation myocardial infarction

Related Article

Inside This Issue
J. Am. Coll. Cardiol. 2009 53: A24. [Full Text] [PDF]

This article has been cited by other articles:

				J. M. Brennan, D. Dai, M. R. Patel, S. V. Rao, E. J. Armstrong, J. C. Messenger, J. P. Curtis, K. A. Shunk, K. J. Anstrom, E. L. Eisenstein, et al. Characteristics and Long-Term Outcomes of Percutaneous Revascularization of Unprotected Left Main Coronary Artery Stenosis in the United States: A Report From the National Cardiovascular Data Registry, 2004 to 2008 J. Am. Coll. Cardiol., February 14, 2012; 59(7): 648 - 654. [Abstract] [Full Text] [PDF]

				T. Y. Wang, F. A. Masoudi, J. C. Messenger, K. A. Shunk, A. Boyle, J. M. Brennan, H. V. Anderson, K. J. Anstrom, D. Dai, E. D. Peterson, et al. Percutaneous coronary intervention and drug-eluting stent use among patients ≥85 years of age in the United States. J. Am. Coll. Cardiol., January 10, 2012; 59(2): 105 - 112. [Abstract] [Full Text] [PDF]

				J. M. Brennan, E. D. Peterson, J. C. Messenger, J. S. Rumsfeld, W. S. Weintraub, K. J. Anstrom, E. L. Eisenstein, S. Milford-Beland, M. V. Grau-Sepulveda, M. E. Booth, et al. Linking the National Cardiovascular Data Registry CathPCI Registry With Medicare Claims Data: Validation of a Longitudinal Cohort of Elderly Patients Undergoing Cardiac Catheterization Circ Cardiovasc Qual Outcomes, January 1, 2012; 5(1): 134 - 140. [Abstract] [Full Text] [PDF]

				L. Venkitachalam, Y. Lei, E. A. Magnuson, P. S. Chan, J. M. Stolker, K. F. Kennedy, N. S. Kleiman, D. J. Cohen, and on behalf of the EVENT Registry Investigators Survival Benefit With Drug-Eluting Stents in Observational Studies: Fact or Artifact? Circ Cardiovasc Qual Outcomes, November 1, 2011; 4(6): 587 - 594. [Abstract] [Full Text] [PDF]

				T. T. Tsai, J. C. Messenger, J. M. Brennan, U. D. Patel, D. Dai, R. N. Piana, K. J. Anstrom, E. L. Eisenstein, R. S. Dokholyan, E. D. Peterson, et al. Safety and Efficacy of Drug-Eluting Stents in Older Patients With Chronic Kidney Disease A Report From the Linked CathPCI Registry-CMS Claims Database. J. Am. Coll. Cardiol., October 25, 2011; 58(18): 1859 - 1869. [Abstract] [Full Text] [PDF]

				Y. J. Hong, M. H. Jeong, A. Abizaid, A. Banning, A. Bartorelli, V. Dzavik, S. G. Ellis, R. Gao, D. R. Holmes Jr, V. Legrand, et al. Sirolimus-Eluting Coronary Stents in Octogenarians: A 1-Year Analysis of the Worldwide e-SELECT Registry J. Am. Coll. Cardiol. Intv., September 1, 2011; 4(9): 982 - 991. [Abstract] [Full Text] [PDF]

				G. W. Stone, A. Rizvi, K. Sudhir, W. Newman, R. J. Applegate, L. A. Cannon, J. T. Maddux, D. E. Cutlip, C. A. Simonton, P. Sood, et al. Randomized Comparison of Everolimus- and Paclitaxel-Eluting Stents: 2-Year Follow-Up From the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV Trial J. Am. Coll. Cardiol., June 28, 2011; 58(1): 19 - 25. [Abstract] [Full Text] [PDF]

				V. J. Bufalino, F. A. Masoudi, S. K. Stranne, K. Horton, N. M. Albert, C. Beam, R. O. Bonow, R. L. Davenport, M. Girgus, G. C. Fonarow, et al. The American Heart Association's Recommendations for Expanding the Applications of Existing and Future Clinical Registries: A Policy Statement From the American Heart Association Circulation, May 17, 2011; 123(19): 2167 - 2179. [Full Text] [PDF]

				B. Witzenbichler, J. Wohrle, G. Guagliumi, J. Z. Peruga, B. R. Brodie, D. Dudek, R. Kornowski, F. Hartmann, K. L. Hood, H. Parise, et al. Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction: The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial Circ Cardiovasc Interv, April 1, 2011; 4(2): 130 - 138. [Abstract] [Full Text] [PDF]

				T.-H. Chen and R. Matyal The Management of Antiplatelet Therapy in Patients With Coronary Stents Undergoing Noncardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2010; 14(4): 256 - 273. [Abstract] [PDF]

				J. S. Rumsfeld and E. D. Peterson Achieving Meaningful Device Surveillance: From Reaction to Proaction JAMA, November 10, 2010; 304(18): 2065 - 2066. [Full Text] [PDF]

				R. J. Krone, S. V. Rao, D. Dai, H. V. Anderson, E. D. Peterson, M. A. Brown, R. G. Brindis, L. W. Klein, R. E. Shaw, W. S. Weintraub, et al. Acceptance, Panic, and Partial Recovery: The Pattern of Usage of Drug-Eluting Stents After Introduction in the U.S. (A Report From the American College of Cardiology/National Cardiovascular Data Registry) J. Am. Coll. Cardiol. Intv., September 1, 2010; 3(9): 902 - 910. [Abstract] [Full Text] [PDF]

				S. Garg and P. W. Serruys Coronary Stents: Current Status J. Am. Coll. Cardiol., August 31, 2010; 56(10_Suppl_S): S1 - S42. [Abstract] [Full Text] [PDF]

				G. W. Stone and S. J. Pocock Randomized Trials, Statistics, and Clinical Inference J. Am. Coll. Cardiol., February 2, 2010; 55(5): 428 - 431. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, G. K. Feld, B. H. Greenberg, J. Hall, M. Hlatky, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, et al. Highlights of the Year in JACC 2009 J. Am. Coll. Cardiol., January 26, 2010; 55(4): 380 - 407. [Full Text] [PDF]

				S. S. Dhruva, L. A. Bero, and R. F. Redberg Strength of Study Evidence Examined by the FDA in Premarket Approval of Cardiovascular Devices JAMA, December 23, 2009; 302(24): 2679 - 2685. [Abstract] [Full Text] [PDF]

				M. A. Hlatky and P. Heidenreich The Year in Epidemiology, Health Services Research, and Outcomes Research J. Am. Coll. Cardiol., December 15, 2009; 54(25): 2343 - 2351. [Full Text] [PDF]

				R. A. Vogel Drug-Eluting Stents: Safe But Not Sufficient J. Am. Coll. Cardiol. Intv., June 1, 2009; 2(6): 513 - 514. [Full Text] [PDF]